Strattera, an attention deficit/hyperactivity disorder (ADHD) medication, is the first FDA-approved non-stimulant to treat ADHD in both adults and children. The drug maker, Eli Lilly, added a bolded warning to the product label on December 17, 2004. The bolded warning indicates that the medication should be discontinued in patients with jaundice (yellowing of the skin or whites of the eyes) or laboratory evidence of liver injury. This label change discusses two reported cases of severe liver injury out of the more than 2 million patients who have taken the medication since approval.

Strattera has also been linked to increases in blood pressure and heart rate.

If you or a loved one has been injured while taking Strattera, please submit the accompanying form. You may be entitled to monetary awards for your injury!